277 related articles for article (PubMed ID: 16365293)
21. Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
From R; Eilam R; Bar-Lev DD; Levin-Zaidman S; Tsoory M; LoPresti P; Sela M; Arnon R; Aharoni R
Glia; 2014 Apr; 62(4):649-65. PubMed ID: 24481644
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis.
Begum-Haque S; Sharma A; Kasper IR; Foureau DM; Mielcarz DW; Haque A; Kasper LH
J Neuroimmunol; 2008 Nov; 204(1-2):58-65. PubMed ID: 18804287
[TBL] [Abstract][Full Text] [Related]
23. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
[TBL] [Abstract][Full Text] [Related]
24. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.
Skihar V; Silva C; Chojnacki A; Döring A; Stallcup WB; Weiss S; Yong VW
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17992-7. PubMed ID: 19815532
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells.
Hammarberg H; Lidman O; Lundberg C; Eltayeb SY; Gielen AW; Muhallab S; Svenningsson A; Lindå H; van Der Meide PH; Cullheim S; Olsson T; Piehl F
J Neurosci; 2000 Jul; 20(14):5283-91. PubMed ID: 10884312
[TBL] [Abstract][Full Text] [Related]
26. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis.
Muhallab S; Lundberg C; Gielen AW; Lidman O; Svenningsson A; Piehl F; Olsson T
Scand J Immunol; 2002 Mar; 55(3):264-73. PubMed ID: 11940233
[TBL] [Abstract][Full Text] [Related]
28. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity.
Moalem G; Gdalyahu A; Shani Y; Otten U; Lazarovici P; Cohen IR; Schwartz M
J Autoimmun; 2000 Nov; 15(3):331-45. PubMed ID: 11040074
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis.
Aharoni R; Eilam R; Lerner S; Shavit-Stein E; Dori A; Chapman J; Arnon R
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948217
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
Aharoni R
J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
[TBL] [Abstract][Full Text] [Related]
31. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.
Aharoni R; Meshorer A; Sela M; Arnon R
J Neuroimmunol; 2002 May; 126(1-2):58-68. PubMed ID: 12020957
[TBL] [Abstract][Full Text] [Related]
32. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.
Aharoni R; Teitelbaum D; Leitner O; Meshorer A; Sela M; Arnon R
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11472-7. PubMed ID: 11027347
[TBL] [Abstract][Full Text] [Related]
33. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.
Chen M; Valenzuela RM; Dhib-Jalbut S
J Neurol Sci; 2003 Nov; 215(1-2):37-44. PubMed ID: 14568126
[TBL] [Abstract][Full Text] [Related]
34. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
35. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
36. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
Aharoni R; Eilam R; Stock A; Vainshtein A; Shezen E; Gal H; Friedman N; Arnon R
J Neuroimmunol; 2010 Aug; 225(1-2):100-11. PubMed ID: 20554028
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis.
Aharoni R; Kayhan B; Arnon R
Inflamm Bowel Dis; 2005 Feb; 11(2):106-15. PubMed ID: 15677903
[TBL] [Abstract][Full Text] [Related]
38. Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Begum-Haque S; Christy M; Wang Y; Kasper E; Ochoa-Reparaz J; Smith JY; Haque A; Kasper LH
J Neuroimmunol; 2013 Jan; 254(1-2):117-24. PubMed ID: 23141166
[TBL] [Abstract][Full Text] [Related]
39. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
Tsai SJ
Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
[TBL] [Abstract][Full Text] [Related]
40. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
